Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Fundamental Analysis

NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD

6.8  +0.86 (+14.48%)

Premarket: 6.81 +0.01 (+0.15%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to UNCY. UNCY was compared to 555 industry peers in the Biotechnology industry. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability. UNCY has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year UNCY has reported negative net income.
In the past year UNCY has reported a negative cash flow from operations.
UNCY had negative earnings in each of the past 5 years.
In the past 5 years UNCY always reported negative operating cash flow.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -119.44%, UNCY is not doing good in the industry: 80.54% of the companies in the same industry are doing better.
UNCY has a Return On Equity of -509.00%. This is in the lower half of the industry: UNCY underperforms 78.74% of its industry peers.
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROIC N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UNCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
UNCY has more shares outstanding than it did 1 year ago.
UNCY has more shares outstanding than it did 5 years ago.
UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

UNCY has an Altman-Z score of 12.74. This indicates that UNCY is financially healthy and has little risk of bankruptcy at the moment.
UNCY has a better Altman-Z score (12.74) than 89.55% of its industry peers.
There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.74
ROIC/WACCN/A
WACC8.93%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

UNCY has a Current Ratio of 1.28. This is a normal value and indicates that UNCY is financially healthy and should not expect problems in meeting its short term obligations.
UNCY's Current ratio of 1.28 is on the low side compared to the rest of the industry. UNCY is outperformed by 84.32% of its industry peers.
UNCY has a Quick Ratio of 1.28. This is a normal value and indicates that UNCY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.28, UNCY is doing worse than 83.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

UNCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.20%, which is quite impressive.
UNCY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)59.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.8%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, UNCY will show a very strong growth in Earnings Per Share. The EPS will grow by 26.28% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.74%
EPS Next 2Y66.28%
EPS Next 3Y59.7%
EPS Next 5Y26.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UNCY. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.83, the valuation of UNCY can be described as very cheap.
Based on the Price/Forward Earnings ratio, UNCY is valued cheaply inside the industry as 99.28% of the companies are valued more expensively.
UNCY is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.49, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.83
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

UNCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as UNCY's earnings are expected to grow with 59.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.28%
EPS Next 3Y59.7%

More info and screens

0

5. Dividend

5.1 Amount

UNCY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (6/27/2025, 8:00:02 PM)

Premarket: 6.81 +0.01 (+0.15%)

6.8

+0.86 (+14.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners52.5%
Inst Owner Change-17.6%
Ins Owners5.22%
Ins Owner Change0%
Market Cap820.28M
Analysts83.08
Price TargetN/A
Short Float %0.31%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)N/A
DP-2.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.77%
Min EPS beat(2)-183.22%
Max EPS beat(2)67.68%
EPS beat(4)2
Avg EPS beat(4)-94.53%
Min EPS beat(4)-285.83%
Max EPS beat(4)67.68%
EPS beat(8)3
Avg EPS beat(8)-69%
EPS beat(12)3
Avg EPS beat(12)-55.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.23%
PT rev (3m)14.29%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-407.69%
EPS NY rev (1m)-616.31%
EPS NY rev (3m)-877.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)16.87%
Revenue NY rev (3m)-28.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.83
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 110.39
P/tB 110.39
EV/EBITDA N/A
EPS(TTM)-5.1
EYN/A
EPS(NY)8.19
Fwd EY120.38%
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 327.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z 12.74
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)153.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.8%
EPS Next Y80.74%
EPS Next 2Y66.28%
EPS Next 3Y59.7%
EPS Next 5Y26.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.38%
EBIT Next 3Y175.15%
EBIT Next 5YN/A
FCF growth 1Y-56.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.29%
OCF growth 3YN/A
OCF growth 5YN/A